Shamburg News · 8-K filed Nov 12, 2026, 7:02 AM EST
Kiora Pharmaceuticals Reports Q3 2026 Net Loss of $1.7 Million and Announces KIO-401 In-Licensing
KPRX · KIORA PHARMACEUTICALS INC
- Earnings
- Materiality: high
On November 12, 2026, Kiora Pharmaceuticals reported a net loss of approximately $1.7 million, or $0.28 per basic and diluted share, for the quarter ended September 30, 2026, compared with net income of approximately $27,000, or $0.01 per share, a year earlier. Collaboration revenue was $1.0 million for the quarter, related to the KIO-301 agreement with Chong Kun Dang Pharmaceutical. The press release also reported approximately $16.3 million in cash and short-term investments and described the in-licensing of KIO-401 from Senju Pharmaceutical.
Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001372514-26-000093.
Written from the filing by Shamburg Markets. Figures are as reported by the company.